The innovation of this study lies in revealing the core role of the FN1-integrin-PI3K/AKT axis and proposing a combined therapeutic strategy targeting both the PI3K/AKT signaling pathway and integrins, providing a new avenue for overcoming therapeutic resistance in pancreatic cancer. This evidence concerns the gene PIK3CA and pancreatic neoplasm.